Company intelligence / Profile preview

Pharmalink International

Hong Kong, Hong Kongpharmalinkinternational.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pharmalink International markets nutraceutical products derived from New Zealand green-lipped mussel oil for both human and animal use. Their flagship brands, Lyprinol®/Lyprinol® Advanced and Antinol®/Antinol® Rapid, are sold in 47 countries. The company is active with over 1,050 shareholders and trades informally over the counter in Hong Kong. No clinical trial data typical of pharmaceutical companies is available as these are nutraceuticals.

Therapeutic areas: Rheumatology
Modalities: Nutraceutical (specifically marine lipid extract from green-lipped mussel)
Industry: Food & Nutrition

Drug pipeline

5 assets

Lyprinol

Commercial

Indications: Inflammation

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pharmalink International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmalink International.

Explore the full profile